Global Digital PCR Market Trends, Growth Analysis, Industry Report, 2026-2034
REPORT DETAILS
Digital PCR Market Summary
The digital PCR market size was valued at USD 817.76 million in 2025. The market is expected to register the highest CAGR of 14.71% from 2026 to 2034. Increasing prevalence of cancer and genetic disorders and upsurging adoption of precision medicine boost the growth of the market.
Market Statistics
Digital PCR Market Key Takeaways
- North America held the largest share of 41.8% in 2025. The region's dominance is attributed to its highly advanced healthcare infrastructure, extensive genomics research, and widespread adoption of molecular diagnostic technologies.
- In North America, the U.S. accounted for 81.6% of the regional market in 2025. Growth is driven by the rising prevalence of chronic conditions, including cancer, cardiovascular diseases, and infectious diseases, along with increasing investments in precision medicine.
- The Asia Pacific dPCR market is expected to register the highest CAGR of 16.21% during the forecast period. Growing healthcare investments, expanding biotechnology research, and increasing adoption of advanced molecular diagnostics across China, India, Japan, and South Korea are expected to bolster market growth.
- The instruments segment accounted for 47.3% of the total market revenue in 2025. Continuous technological advancements in digital PCR platforms, improved automation, and increasing laboratory adoption are supporting the segment's leadership.
- The research applications segment held the largest market share of 45.8% in 2025. High demand for digital PCR in genomics research, biomarker discovery, gene expression analysis, and precision medicine is driving the widespread adoption of this technology in research activities.
- The droplet digital PCR dominated with largest share of 63.21% in 2025 due to its simple workflow. Droplet digital PCR are easy to use and are highly sensitive for target detection
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
What Is Digital PCR? Absolute Nucleic-Acid Quantification Explained
Digital PCR, a specialized form of endpoint PCR, is tailored for absolute quantification and the analysis of minority sequences within a background of predominant sequences. This technology excels in precision and sensitivity for nucleic acid quantification, driving its increasing adoption across various applications. In contrast, traditional PCR, which relies on agarose gel electrophoresis to detect amplified products, offers semi-quantitative results and is being gradually supplemented by the higher accuracy and reliability of digital PCR technologies in the expanding digital PCR market.
The rise in diabetic cases has boosted the need for accurate diagnostic tools, driving demand in the digital PCR (polymerase chain reaction) market. Digital PCR technology provides highly precise and sensitive detection of genetic markers linked to diabetes, facilitating early diagnosis and personalized treatment strategies. Its capability to detect infrequent modifications and quantify target DNA with remarkable precision is crucial for observing disease advancement and assessing treatment effectiveness in diabetic patients. Furthermore, ongoing research and development efforts drive innovations in product development, continually enhancing the efficiency, accuracy, and speed of digital PCR systems.
How Digital PCR Works: Partitioning, Amplification, and Absolute Quantification
- Target DNA/RNA is mixed with primers, reagents, and probes.
- The mix is then diluted and split into tens of thousands of nanoliter droplets. Ideally, one target copy per droplet.
- Each plate/droplets undergo independent PCR cycling.
- Positive droplets glow above a certain threshold. Negative droplets stay dark.
- Partitions follow a Poisson distribution. The system count positive vs. negative droplets. Apply Poisson statistics.
- Software delivers absolute copy-number results. No standard curve needed.
Digital PCR vs qPCR: Accuracy, Sensitivity, Cost and Applications
| Factor | Digital PCR (dPCR) | Quantitative PCR (qPCR) |
| Quantification | Absolute quantification | Relative quantification (requires standard curves) |
| Sensitivity | Very high. Detects rare mutations and low-abundance targets | High. But less sensitive for rare mutations |
| Accuracy | Higher precision with minimal variability | Good accuracy but depends on amplification efficiency |
| Standard Curve | Not required | Required for absolute quantification |
| Workflow Speed | Slower due to sample partitioning | Faster with shorter turnaround time |
| Cost | Higher instrument and reagent costs | Lower equipment and operating costs |
| Sample Partitioning | Yes; sample divided into thousands of microreactions | No; reaction occurs in a single tube |
| Common Applications | Liquid biopsy, rare mutation detection, copy number variation, minimal residual disease | Gene expression analysis, viral load testing, pathogen detection, routine diagnostics |
| Preferred Use | Precision diagnostics and research requiring maximum sensitivity | Routine clinical testing and high-throughput laboratories |
Source: Polaris Market Research Analysis
AI and Automation in Digital PCR Data Analysis and Assay Optimization
- AI-powered data analysis tools enable automation in fluorescence signal interpretation and partition classification. The tools improve quantification accuracy. They also reduce the time required for manual data analysis.
- Machine learning is used for automated assay optimization. ML algorithms assist in primer/probe design and assay parameter optimization. They accelerate test development and enhance reproducibility.
- Use of robotics increases productivity and minimizes chances of human mistakes.
- AI technology integrates the information obtained from digital PCR analysis with genomics and clinical data. It helps in biomarker discovery, precision oncology, and personalized treatment.
- AI analytics minimize operational costs and help with reagent inventories, instrument usage, maintenance scheduling, and laboratory resources.
Digital PCR Market Dynamics
Driver: Increasing Demand in Molecular Diagnostics & Precision Medicine
Digital PCR is increasingly embedded in precision medicine and genetic testing workflows. Digital PCR offers absolute quantification. It enables more accurate disease detection and treatment monitoring compared to traditional PCR methods. It has sensitivity to rare mutations and low-abundance targets. Thus, dPCR has become a preferred tool across clinical diagnostic pipelines. Digital PCR facilitates early disease detection. It recognizes rare genetic mutations and biomarkers even before the emergence of symptoms. Further, dPCR provides assistance in patient stratification for cancer and rare disease treatments.
Driver: Technological Advancements in Digital PCR
Market CAGR for digital PCR is being driven by technological advancements, such as continuous improvements in digital PCR technologies that have led to enhanced precision and sensitivity in nucleic acid quantification. This allows for more accurate detection of genetic mutations, rare sequences, and low-abundance targets, which is crucial in both clinical diagnostics and research settings. Innovations in automation have streamlined workflows and increased throughput in digital PCR systems. Automated platforms reduce human error, improve efficiency, and enable high-throughput processing of samples, thereby meeting the growing demand for scalability and rapid analysis in laboratories. Furthermore, advancements in digital PCR technology and an increasing number of product launches in the global market are expected to drive growth in the digital PCR industry.
Driver: Rising Prevalence of Cancer
The digital PCR market is witnessing substantial growth, mainly driven by the increasing prevalence of cancers such as lung cancer, blood cancer, and brain tumors. According to American Cancer Society, 2,041,910 new cancer cases were recorded in U.S. in 2025. This significant burden underscores the increasing healthcare expenditures in developing countries. Cancer management requires precise, sensitive molecular diagnostics for accurate detection and monitoring. Digital PCR tests play a crucial role in molecular cancer diagnosis, offering enhanced capabilities in detecting rare mutations and monitoring disease progression. As the demand for accurate and early cancer detection rises, digital PCR technology is becoming increasingly indispensable in oncology, contributing significantly to the digital PCR market revenue (Source: cancer.org).
Driver: Cell and Gene Therapy Manufacturing:
Rising production of cell and gene therapies is driving demand for digital PCR instrumentation. Cell and gene therapies require rigorous analysis during research and development and manufacturing to ensure potency, consistency, and safety. Digital PCR enables highly sensitive nucleic acid detection and quantification. In addition, as cell and gene therapies proceed to the clinic and scale toward commercial manufacturing, the need for digital PCR expands to meet the requirements for a wide range of assays across research, development, and manufacturing. Thus, the rising emphasis on CGT manufacturing is driving the industry growth.
Restraint: Lack of Assay Standardization
The lack of assay standardization is a significant constraint that could hinder the adoption of digital PCR. The technology includes varying methods, materials, and procedures across different laboratories. It impacts the uniformity and inter-comparison of test results. This also creates a challenge while validating assays, thus increasing the time and cost of research and development. The manufacturers need to comply with the diverse needs of the industry in terms of application and geography, which is a difficult task and can result in the technology’s lesser adoption compared to conventional methods.
Restraint: Reimbursement Limits and NGS Substitution
The limited or no reimbursement for the tests offered by digital PCR tests limits its adoption in the clinical setting. The high cost of tests offered by digital PCR further discourage the target end-users from adapting the technology. The emergence of next-generation sequencing (NGS) enables extensive genetic analysis, which offers an extensive look into the genetic makeup and hereditary information of the studied samples. Thus, in terms of application, NGS provides an alternative approach to digital PCR, which could further impact the market growth.
Opportunity: Increasing Preference for Liquid Biopsy
The growing use of liquid biopsy is creating opportunities in the digital PCR market. Liquid biopsy enables non-invasive diagnosis by detecting genetic information from cancer cells and other diseases through blood tests. Digital PCR technology can be utilized in liquid biopsy for the accurate detection and quantification of genetic material. These advancements in early detection, monitoring of treatment, and tracking of disease progression is expected to fuel the demand for liquid biopsies. Moreover, the shift toward less invasive diagnostic procedures among clinicians and researchers is further fueling the demand for liquid biopsies, thus, driving the digital PCR market growth.
Opportunity: Rising Focus on MRD & Companion Diagnostics
The rising application of minimal residual disease (MRD) and companion diagnostics is providing new growth opportunities for the digital-PCR market. MRD analysis is utilized in detecting minute traces of cancerous cells and determines the response of cancer to treatment. Digital PCR can be used in various MRD tests for the detection of genetic variations. Similarly, companion diagnostics can be used for detecting biomarkers to identify suitable therapy for patients. Both these applications are witnessing a significant rise due to the growing need for targeted cancer therapies and personalized medicine, which is expected to drive the growth of the digital PCR market during the forecast period.
Key Applications of Digital PCR
Digital PCR in Infectious Disease Monitoring
Digital PCR plays a growing role in infectious disease surveillance, where its ability to detect low viral loads improves both individual diagnosis and population-level outbreak monitoring. This capability was demonstrated at scale during the COVID-19 pandemic, when platforms such as Bio-Rad's PREvalence ddPCR SARS-CoV-2 kit were deployed for wastewater-based surveillance.
Digital PCR in Oncology
ctDNA Mutation Detection & Therapy Selection: Digital PCR allows detecting the amount of circulating tumor DNA (ctDNA) in blood. ctDNA fragments contain genetic information about cancer cells in the form of point mutations. Digital PCR is a sensitive tool that identifies small amounts of these fragments and determine their location. This non-invasive test helps make informed decisions about the therapy by providing genetic information about a tumor. The liquid biopsy technology is further used to monitor therapy by assessing small amounts of DNA in blood.
Minimal Residual Disease & Recurrence Monitoring: Digital PCR enables the identification of minimal residual disease (MRD) by detecting tumoral cell DNA fragments in blood. MRD refers to the presence of cancer in the body after successful treatment. Information about MRD helps to estimate if the therapy has been effective. Moreover, serial liquid biopsies allow monitoring the cancer-free status of the patient. If fragments of DNA are detected in the blood, this indicates a potential recurrence. Therefore, digital PCR minimal residual disease is valuable tool for detection and monitoring of cancer.
Digital PCR vs NGS liquid biopsy: What is the Difference and how both can work simultaneously
Digital PCR and next-generation sequencing (NGS) can support each other in liquid biopsy testing. While NGS can determine the range of genetic variants associated with cancer development, digital PCR liquid biopsy can be used to estimate the level of specific point mutations within a single sample. This combined approach to liquid biopsy allows assessing the overall tumor genome and monitoring some particular mutations. Thus, it can be helpful in cases when a physician needs to determine the specific genetic variations associated with cancer progression.
Digital PCR Market Segment Insights
Digital PCR Product Offering Insights
The global digital PCR market segmentation, based on product offering, includes reagents & consumables, instruments, software, and services. In 2025, the instruments segment accounted for the largest market share of 47.3%. Instruments in the digital PCR market encompass the hardware and equipment necessary to perform digital PCR tests, including dPCR systems, thermal cyclers, and associated consumables. Continuous innovations in dPCR instruments have improved their sensitivity, accuracy, and throughput, making them more efficient and reliable for molecular diagnostics and research applications.
Manufacturers are expanding their product portfolios and geographic presence through strategic partnerships, collaborations, acquisition, and product launches. For instance, in July 2025, Bio-Rad launched four droplet digital PCR platforms. This product launch was made through Stilla Technologies, which was acquired by Bio-Rad recently. This expansion aims to meet the diverse needs of customers and capitalize on emerging market opportunities (Source: investors.bio-rad.com).
Digital PCR Technology Insights
The global digital PCR market segmentation, based on technology, includes droplet digital PCR, BEAMing digital PCR, microfluidic digital PCR, and Chip-based Digital PCR. The droplet digital PCR dominated with largest share of 63.21% in 2025 due to its simple workflow. Droplet digital PCR are easy to use and are highly sensitive for target detection. It divides a single reaction sample into approximately 20,000 individual nanoliter-scale water-in-oil droplets. This allows single-molecule detection and absolute quantification. Moreover, rising demand for the cell and gene therapy is further driving the demand for the droplet digital PCR technology. Digital PCR cell and gene therapy enables precise quantification, thereby driving the droplet digital PCR market growth.
Digital PCR Application Insights
The global digital PCR market segmentation, based on application, includes clinical applications, research applications, forensic applications, environmental applications, and other applications. The research application segment held the largest market share of 45.8% in 2025. Researchers in genetics, molecular biology, and biomedical sciences need precise tools for nucleic acid quantification. Digital PCR offers accuracy and sensitivity, ideal for research applications driving the research segment in the digital PCR market. Furthermore, forensic genomic applications are expected to grow significantly during the forecast period due to rising collaborations between academic institutions, research organizations, and market key players. The players have facilitated the integration of digital PCR into various research projects. These partnerships help in the development of new applications and expand the reach of dPCR technology.
Digital PCR End User Insights
The global digital PCR market segmentation, based on end user, includes hospitals & clinical laboratories, academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, others. The hospitals & clinical laboratories segment held the largest market share of 41.77% in 2025 as hospitals and clinical laboratories are major end users of digital PCR systems. These facilities use digital PCR for cancer testing, genetic testing, infectious disease testing, and treatment monitoring. The growing focus on early disease detection and personalized care is increasing demand for accurate testing. Digital PCR further supports the detection of small amounts of genetic material in patient samples. As hospitals expand advanced diagnostic services and laboratories adopt faster testing methods, the use of digital PCR is expected to grow.
Real-World Use Cases of Digital PCR
| Application | Real-world example | How dPCR is used |
| Liquid biopsy — targeted therapy selection | EGFR mutation testing from blood in non-small cell lung cancer | Detects low-fraction ctDNA mutations without repeat tissue biopsy |
| Minimal residual disease (MRD) | BCR::ABL1 transcript monitoring in chronic myeloid leukemia; QIAGEN is developing a BCR::ABL assay for QIAcuityDx | Quantifies residual disease after treatment and flags relapse early |
| Viral load & wastewater surveillance | SARS-CoV-2 wastewater programs (Bio-Rad PREvalence, QIAGEN–GT Molecular); HIV and hepatitis B/C load monitoring | Quantifies very low viral concentrations in clinical and environmental samples |
| Rare genetic mutations & copy number | SMN copy-number analysis in spinal muscular atrophy; cystic fibrosis and DMD variants | Resolves copy number and low-frequency variants missed by conventional PCR |
| Cell & gene therapy QC | Bio-Rad Vericheck ddPCR kits (July 2026) for capsid analysis, mycoplasma and residual DNA | Vector copy number, AAV titer, residual host-cell DNA in manufacturing |
| Organ transplant monitoring | Stilla (Bio-Rad) Nio systems positioned for transplant testing | Measures donor-derived cell-free DNA as a rejection marker |
Source: Polaris Market Research Analysis
Digital PCR Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominated the digital PCR market share with 41.8% in 2025 due to its highly developed healthcare infrastructure, which facilitates the adoption of advanced technologies like PCR. Hospitals, diagnostic laboratories, and research institutions in the region are well-equipped with advanced tools and resources to invest in sophisticated diagnostic and research technologies, further driving the market growth. The key market players are merging, acquiring, and collaborating to strengthen their market presence and serve better offerings in North America, further driving the market during the forecast period.
The U.S. digital PCR market held the largest market share of 81.6% in 2025, primarily due to the high prevalence of chronic diseases such as cancer, cardiovascular diseases, and infectious diseases. The precision and sensitivity of dPCR make it an indispensable tool for early diagnosis, disease monitoring, and personalized treatment, thereby driving its demand in clinical diagnostics. The market is further bolstered by the strong presence of leading companies such as Bio-Rad Laboratories, Thermo Fisher Scientific, and Qiagen. Their extensive distribution networks and continuous product innovations instill confidence in the digital PCR market's stability and growth.
The Canada digital PCR market is expected to witness growth of CAGR 16.3% during the forecast period due to continuous technological innovations leading to improvements in dPCR platforms. These advancements enhance accuracy, efficiency, and ease of use, attracting more users and expanding the applications of dPCR in various fields. The collaboration between key players demonstrates the potential of dPCR technology in providing reliable and timely data, boosting confidence in its applications, and driving the market for the future.
Asia Pacific
The digital PCR market Asia Pacific is projected to experience the highest compound annual growth rate (CAGR) of 16.21% during the forecast period. Many countries in the Asia-Pacific region are significantly increasing their healthcare budgets. Governments and private sectors are investing in advanced healthcare technologies, including molecular diagnostics, to improve healthcare infrastructure and patient outcomes. This investment fuels the adoption of innovative diagnostic tools like dPCR.
India digital PCR market held the largest market share of 37.28% in 2025 due to the rising prevalence of chronic diseases such as cancer, infectious diseases, and genetic disorders. On the other hand, China's digital PCR market is expected to record fastest growth of CAGR 16.9% during the forecast period, with heavy investments in biotech research leading to increased use of dPCR technology in various research applications.
Europe
The digital PCR market in Europe is expected to witness growth of CAGR 15.1% during the forecast period driven by the rising need for high-end diagnostic testing and a rise in cancer cases, which propel the demand for genetic testing and treatment. Moreover, the region witnesses robust healthcare infrastructure development and incorporation of personalized medicine. Additionally, there is a significant amount of genomic and biotech R&D taking place in the region. Along with this, government support for high-end medical technologies is growing exponentially in the region. Moreover, liquid biopsy and minimal residual disease tests are being used extensively for cancer detection.
The Germany digital PCR market is expected to witness growth of CAGR 16.4% during the forecast period driven by the surging need for high-end diagnostic testing and increasing use of molecular diagnostic tests. Moreover, the rising cancer screening and personalized treatment trends are anticipated to drive the market during the forecast period. Germany is a part of leading biotechnology and pharmaceutical hubs in the world that are involved in intense research to develop advanced treatment methodologies. This factor is expected to fuel the demand for nucleic acid-based research tools. Advancements in genomics and the rising need for precision medicine are other crucial factors influencing the market in the region. In addition, the utilization of digital PCR in cancer detection and personalized treatment is expected to augment the market growth in the country.
The France digital PCR market is expected to witness growth of CAGR 15.3% during the forecast period due to rise in government spending in the healthcare and biotechnology sector. Government in the country is investing heavily in the healthcare and biotechnology sector which is driving the demand for the PCR in the biotechnology academic and research application. Moreover, expansion of the healthcare facilities are further driving the demand for the dPCR for diagnostics, thereby driving the growth.
The UK is expected to witness growth of CAGR 16.2% during the forecast period due to large healthcare infrastructure. The country has one of the most advance healthcare infrastructures which fuels the demand for the digital PCR for diagnostics of infectious disease. Moreover, expansion of biotechnology research laboratories in the region further drives the demand for the digital PCR in the country, thereby fueling the industry growth.
Latin America
The Latin American digital PCR market is expected to witness growth of CAGR 13.8% during the forecast period driven by a rise in cancer cases and the need for high-end genetic testing and treatment. Moreover, the region is witnessing a growing inclination towards adopting new technologies in the healthcare sector. There is an increase in investment in the healthcare sector, rising number of diagnostic labs, and favorable government policies regarding advanced laboratory equipment. In addition, extensive R&D activities in biotechnology and genomics are taking place in the region. Moreover, the growing need for personalized medicine and liquid biopsy in the region is expected to drive the market growth.
The Brazil digital PCR market expected to witness growth of CAGR 14.7% during the forecast period driven by the rising need for high-end diagnostic testing and increasing incidence of cancer across the population. Moreover, the government is focusing on the development of modern healthcare infrastructure and new treatment methodologies. Increasing investment in the biotechnology and research sector is expected to augment the demand for digital PCR technology in the country. The rising use of personalized medicine and liquid biopsy technologies is projected to propel the market growth in the country.
Middle East & Africa
The Middle East & Africa digital PCR market is expected to witness growth of CAGR 13.4% during the forecast period driven by the rising need for high-end diagnostic testing and increasing incidence of cancer across the population. Moreover, the region is witnessing significant healthcare infrastructure development and investment in advanced laboratory equipment. The growing need for personalized medicine is also supporting the market growth in the region. In addition, extensive R&D activities in biotechnology and genomics are taking place in the region. Moreover, increased investment in the healthcare sector is expected to drive the market growth in the region.
The UAE digital PCR market is expected to witness growth of CAGR 14.3% during the forecast period driven by the rising need for high-end diagnostic testing and increasing incidence of cancer across the population. Moreover, the UAE government is focusing on the development of modern healthcare infrastructure and new treatment methodologies. The growing need for personalized medicine and extensive R&D activities in the field of genomics and biotechnology are anticipated to drive the market growth.
Digital PCR Market Competitive Landscape
Leading market players are driving innovation and expanding the application scope of this advanced molecular technology. Digital PCR manufacturers focus on strategic partnerships, product launches, and extensive research and market development activities to maintain their competitive edge and meet the growing demand for precise nucleic acid quantification. The competitive landscape is dynamic, with continuous advancements and strategic initiatives shaping the future of the dPCR industry.
The digital PCR market is poised for significant growth, driven by the efforts of key players to innovate, collaborate, and expand their reach, which drives the global digital PCR industry.
List of Key Digital PCR Companies
-
Bio-Rad Laboratories, Inc.
-
JN Medsys
-
Precigenome LLC
-
QIAGEN N.V.
-
Standard BioTools Inc.
-
Sysmex Corporation
-
Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe)
-
OPTOLANE Technologies Inc.
-
TargetingOne Corporation., Ltd
Vendor Market Positioning
| Company | HQ | dPCR Platform(s) | Partition Technology | Market Positioning |
| Bio-Rad Laboratories, Inc. | Hercules, California, U.S. | QX200, QX600, QX Continuum, QX700 series (ex-Stilla Nio) | Droplet (water-in-oil) | Category pioneer and installed-base leader in droplet digital PCR. Now spans entry level (QX Continuum) to higher-automation systems after absorbing Stilla’s technology as the QX700 series (acquisition closed 30 Jun 2025). Strategy is to move from research into applied research and clinical diagnostics. Vericheck CGT QC kits (2026) as supplied; not independently verified. |
| QIAGEN N.V. | Venlo, Netherlands | QIAcuity family (incl. QIAcuity One), QIAcuityDx | Nanoplate | Integrated, automated nanoplate workflow with the strongest assay ecosystem push. dPCR is one of five named 2026 growth drivers; QIAcuityDx (launched Oct 2024) targets clinical MRD and monitoring, with three pharma companion-diagnostic partnerships. June 2026 expansion into gene expression takes dPCR into qPCR territory. 3,200+ placements as supplied; not independently verified. |
| Thermo Fisher Scientific Inc. | Waltham, Massachusetts, U.S. | QuantStudio Absolute Q | Microfluidic array plate (microchamber array) | Workflow-simplicity play: first fully integrated dPCR system (digitization, thermal cycling and read in one instrument; ~90 minutes, ~5 minutes hands-on), built on the 2021 Combinati acquisition. Leverages the broad assay catalogue and qPCR installed base; core applications are oncology and cell and gene therapy. |
| F. Hoffmann-La Roche Ltd. | Basel, Switzerland | Digital LightCycler | Nanowell plate (20,000 / 28,000 / 100,000-partition formats) | IVD-intended system (CE-marked, FDA 510(k)-exempt at launch in Aug 2022) with 6 optical channels and 5x concentrated master mixes; pitched at MRD, CNV, cfDNA, rare mutation and gene expression work. Strength is global diagnostics channel and PCR heritage; no dPCR-specific announcement found since launch. |
| Sysmex Corporation | Kobe, Japan | OncoBEAM (via Sysmex Inostics GmbH) | BEAMing (emulsion dPCR + flow cytometry) | Oncology liquid-biopsy specialist rather than a platform seller. OncoBEAM RAS CRC kit (CE-IVD, 34 RAS mutations) and EGFR kit v2 (RUO, 36 mutations); US CLIA-certified lab for clinical and biopharma testing. High-sensitivity niche; no recent dated news found. |
| TargetingOne Corporation., Ltd | Beijing, China | D30 and D50 Automatic Digital PCR Systems; TD-1 series | Micro-droplet (chip-integrated) | Instrument-plus-reagent model: its dPCR kit was the first in China to receive NMPA Class III registration, and TD-1 was the first Chinese dPCR export. |
| Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe) | Shenzhen, China | Molecision S6 | Droplet (chip-based; >25,000 droplets, <0.8 nL) | Diagnostics major extending from immunoassay (MAGLUMI) into molecular. Fully integrated droplet generation, PCR, reading and analysis in one analyzer; 16 samples per run, 5 fluorescence channels, ~2.5-hour run; positioned for research and IVD. Gains from Snibe’s global distributor network. |
| Precigenome LLC | San Jose, California, U.S. | DropXpert series | Droplet | Droplet-based dPCR vendor; limited public information found. Chip-integrated “sample-in, result-out” droplet platforms of this type are being validated clinically (e.g., CML). Snibe’s Molecision S6 specifications look similar to the DropXpert S6; a possible OEM or partnership link needs confirming. |
| OPTOLANE Technologies Inc. | Seongnam, South Korea | LOAA dPCR / digital real-time PCR analyzer; Dr. PCR kits | Semiconductor (CMOS) chip, microwell array | Compact digital real-time PCR that outputs absolute quantification and an amplification curve together; company cites ~1-hour turnaround versus 4+ hours for other dPCR. IVD focus: Dr. PCR BCR-ABL1 kit (CML monitoring); COVID-19 viral-load kit received emergency-use approval in Korea. |
| JN Medsys | Singapore | Clarity, Clarity Plus+ | Chip-in-a-tube (high-density chip in tube strip; 10,000 partitions, 40,000+ on Plus+) | Low-cost, easy-to-adopt research system that runs on conventional thermal cyclers (up to 96 reactions per run, 4–6 colour on Plus+). Distribution in Japan (LMS), China, South Korea, Hong Kong and Taiwan; stated ambition to pursue IVD approvals. No recent dated news found. |
| Standard BioTools Inc. | Boston, Massachusetts, U.S. | Biomark microfluidic IFC-based digital arrays | Integrated fluidic circuits | Formerly Fluidigm; dPCR is a legacy microfluidics line for research and biopharma within a broader tools portfolio. The company is in strategic transition (pending merger with Treeline Biosciences, mass cytometry divestiture), so dPCR investment looks limited. |
Source: Polaris Market Research Analysis
Digital PCR Industry Developments
-
July 2026: Bio-Rad Laboratories launched Vericheck droplet digital PCR (ddPCR) kit portfolio. The ddPCR kits can be used for quality control in cell and gene therapy manufacturing. The kit offers validated workflows for capsid analysis, mycoplasma detection, and residual DNA quantification. (Source: clpmag.com)
-
June 2026: QIAGEN expanded its QIAcuity digital PCR portfolio with new gene expression assays, multiplex capabilities, cell and gene therapy testing, automated analysis, reporting, and Hamilton integration. The company said these additions strengthened adoption across research, biopharma, and high-throughput laboratory workflows. (Source: corporate.qiagen.com)
-
October 2025: Biodesix and Bio-Rad expanded partnership agreement to developed droplet digital PCR technology. (Source: biospace.com)
-
October 2025: Bio-Rad Laboratories signed a strategic agreement with Gencurix, Inc. With this deal, Bio-Rad will distribute Gencurix' CE-IVD Droplex digital PCR oncology testing kits across Europe. (Source: news-medical.net)
Future Outlook of Digital PCR Market
According to our digital PCR market forecast 2034, the market is expected to grow steadily during the forecast period. The growth will be attributed to the increasing demand for ultra-sensitive diagnostics and precision medicine. Expanding applications in oncology and infectious diseases would boost market expansion. Furthermore, rising technological advancements in droplet and chip-based systems will fuel market penetration. There is an increasing integration of digital PCR with AI and automation. It will improve efficiency and scalability in molecular diagnostics. Adoption of such technologies would offer lucrative business opportunities in the coming years.
Research Methodology
- Market estimates are derived using a blend of primary and secondary research, validated through weighted-average and combined top-down/bottom-up modeling approaches.
- Secondary research covers company filings, clinical trial registries, molecular diagnostics regulatory approvals, genomics research publications, industry journals, and paid third-party databases to build baseline estimates.
- Primary research includes interviews with key industry participants such as digital PCR instrument manufacturers, clinical laboratory directors, genomics researchers, and CRO/CDMO professionals, to validate accuracy and capture forward-looking insights.
- Base year considered is 2025, with a forecast provided through 2034; revenues are expressed in USD Million.
- Parent market is identified as the global PCR and molecular diagnostics market; the addressable segment is narrowed using digital PCR adoption rates across clinical, research, and forensic applications.
- Bottom-up model aggregates regional digital PCR demand across product offering, technology, application, and end user, validated against vendor revenue disclosures from Bio-Rad Laboratories, Thermo Fisher Scientific, QIAGEN, F. Hoffmann-La Roche, and others.
- Regional coverage spans North America, Europe, Asia Pacific, Middle East & Africa, and Latin America, further segmented by major countries.
- Projected 14.71% CAGR reflects weighted analysis of rising demand for high-precision quantification in liquid biopsy and oncology testing, growing adoption in infectious disease monitoring, expanding use in prenatal and genetic testing, and increasing pharmaceutical R&D investment in gene and cell therapy development.
- Findings are cross-validated across multiple estimation methods to ensure consistency, accuracy, and reliability of the final market sizing.
Digital PCR Market Segmentation:
By Product Offering Outlook (Revenue, USD Million, 2021–2034)
- Reagent & Consumables
- Instruments
- Software
- Services
By Technology Outlook (Revenue, USD Million, 2021–2034)
- Droplet Digital PCR
- Beaming Digital PCR
- Microfluidic Digital PCR
- Chip-based Digital PCR
By Application Outlook (Revenue, USD Million, 2021–2034)
- Clinical Applications
- Research Applications
- Forensic Applications
- Environmental Applications
- Other Applications
By End User Outlook (Revenue, USD Million, 2021–2034)
- Hospitals and Diagnostic Laboratories
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
- CROs and CDMOs
- Forensic Laboratories
- Other End Users
By Regional Outlook (Revenue, USD Million, 2021–2034)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia-Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Digital PCR Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 817.76 Million |
| Market Size in 2026 | USD 936.03 Million |
| Revenue Forecast in 2034 | USD 2,811.77 Million |
| CAGR | 14.71% from 2026 – 2034 |
| Base year | 2025 |
| Historical data | 2021 – 2024 |
| Forecast period | 2026 – 2034 |
| Quantitative units | Revenue in USD million and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments covered |
|
| Regional scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
Source: Polaris Market Research Analysis
Digital PCR Market FAQs
The market was valued at USD 817.76 million in 2025 and is expected to reach 2,811.77 million by 2034.
The market is expected to grow at a 14.71% CAGR during the forecast period.
A method that splits a sample into thousands of partitions, amplifies each, and counts positives to give an absolute DNA/RNA copy number without a standard curve.
dPCR gives absolute quantification and detects rare variants at lower allele fractions; qPCR needs a standard curve but is faster and cheaper per sample.
North America dominated the global market with a 41.8% share in 2025. In the region, the U.S. accounted for 81.6% revenue share.
The market in Asia Pacific is expected to record the fastest CAGR of 16.21 % over 2026–2034.
The instruments segment accounted for the largest share of 47.3% in 2025.
The research applications segment held the largest share of 45.8% in 2025.
It detects and tracks known tumor mutations (e.g., EGFR in NSCLC) in circulating tumor DNA from a blood draw, supporting therapy selection and minimal residual disease monitoring.
Bio-Rad Laboratories, Thermo Fisher Scientific, QIAGEN, Roche, Sysmex, Standard BioTools, JN Medsys, and Precigenome, among others.
Download Sample Report of Digital PCR Market
Please fill out the form to request a customized copy of the research report.
